

In re Application of:  
Lee *et al.*  
Application No.: 09/361,655  
Filed: July 27, 1999  
Page 2

PATENT  
Attorney Docket No.: JHU1220-4



RECEIVED

DEC 7 2000

**IN THE SPECIFICATION:**

At page 1, following the title, please delete the previous priority information and replace with: **TECH CENTER 1600/2900**

**CROSS REFERENCE TO RELATED APPLICATIONS**

C1  
This application is a divisional of U.S. Application Serial No. 08/765,662, filed April 28, 1997, now U.S. Patent No. 5,929,213, which application claims priority under 35 U.S.C. §120 to PCT/US95/08745, filed July 12, 1995, which application is a continuation-in-part of U.S. Application Serial No. 08/274,215, filed July 13, 1994, now U.S. Patent No. 5,831,054, and to U.S. Patent Application Serial No. 09/184,933, filed November 2, 1998, now U.S. Patent No. 6,130,050, which application is a divisional of U.S. Application Serial No. 08/274,214, now U.S. Patent No. 5,831,054.

**IN THE CLAIMS:**

All of the claims have been reiterated for the convenience of the Examiner.

✓ Please cancel claim 17, without prejudice.

Please amend the claims as follows:

15. (Twice Amended) A method of detecting a [cell proliferative] liver disorder comprising contacting an antibody that specifically binds to growth differentiation factor-12 (GDF-12) polypeptide having an amino acid sequence as set forth in SEQ ID NO:12 with a [specimen] liver specimen [of] from a subject [suspected of having a GDF-12 associated disorder] and detecting binding of the antibody under conditions suitable for formation of a complex; and comparing the amount of complex in the liver specimen to the amount in a control sample, wherein a difference is indicative of a liver disorder.

G3 16. (Amended) The method of claim 15, wherein the [cell] specimen contains [is] a liver cell.

17. (Canceled) The method of claim 15, wherein the detecting is *in vivo*.